Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of “Moderate Buy” by Analysts

Elanco Animal Health Incorporated (NYSE:ELAN) has earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $27.6667.

Several brokerages have recently issued reports on ELAN. Wall Street Zen upgraded shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 19th. KeyCorp upped their target price on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday, December 29th. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Finally, Barclays initiated coverage on shares of Elanco Animal Health in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 target price for the company.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $22.95 on Wednesday. The company has a market capitalization of $11.41 billion, a PE ratio of -47.80, a price-to-earnings-growth ratio of 2.92 and a beta of 1.83. Elanco Animal Health has a one year low of $8.02 and a one year high of $27.72. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.08. The company’s fifty day moving average price is $24.52 and its 200 day moving average price is $22.24.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The business’s revenue was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Institutional Trading of Elanco Animal Health

Institutional investors have recently modified their holdings of the company. Primecap Management Co. CA raised its stake in shares of Elanco Animal Health by 3.1% in the second quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock valued at $739,230,000 after purchasing an additional 1,543,279 shares in the last quarter. Vanguard Group Inc. increased its holdings in Elanco Animal Health by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 48,586,708 shares of the company’s stock valued at $978,536,000 after buying an additional 759,623 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in Elanco Animal Health by 11.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock valued at $797,197,000 after buying an additional 3,717,404 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Elanco Animal Health by 1.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 25,082,545 shares of the company’s stock valued at $567,622,000 after buying an additional 373,869 shares in the last quarter. Finally, UBS Group AG raised its stake in shares of Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after buying an additional 5,961,457 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.